Journals / Erciyes Medical Journal / 2016 / Cilt: 38 - Sayı: 1

Thyrotropinomas: Presentation of Three Cases and Review of Literature

Pages
32–37
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, thyrotropinomas are increasingly being encountered when they are smaller, which has improved patient prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Thyrotropinomas are rare pituitary tumors that are difficult to diagnose due to their variety of clinical presentations.
📊
Key Findings & Data:Patient 1 had a typical acromegalic phenotype with a pituitary adenoma that secreted both growth hormone (GH) and thyroid-stimulating hormone (TSH).
💡
Conclusion & Impact:In conclusion, thyrotropinomas are increasingly being encountered when they are smaller, which has improved patient prognosis.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Thyrotropinomas are rare pituitary tumors that are difficult to diagnose due to their variety of clinical presentations. We describe three patients with thyrotropinoma and review the management of this disease based on current literature. Patient 1 had a typical acromegalic phenotype with a pituitary adenoma that secreted both growth hormone (GH) and thyroid-stimulating hormone (TSH). Patient 2 underwent pituitary surgery without antithyroid treatment; this tumor was also positive for both TSH and GH on pathological examination, and the patient experienced transient central hypothyroidism postoperatively. Patient 3, who had both a thyrotropinoma and autoimmune thyroiditis, underwent surgery after one year of treatment with lanreotide; the removed pituitary adenoma was positive only for TSH. To our knowledge, concomitant Graves' disease and thyrotropinoma is very rare, with only two patients previously reported. In conclusion, thyrotropinomas are increasingly being encountered when they are smaller, which has improved patient prognosis. Nevertheless, the diagnosis and perioperative management of thyrotropinomas remain challenging, which suggests that patients with such tumors should be managed by endocrinologists.

🔖

Cite This Article

DİRİ, H., ŞİMŞEK, Y., KARACA, Z. C. Ö., KELEŞTİMUR, F. (2016). Thyrotropinomas: Presentation of Three Cases and Review of Literature. Erciyes Medical Journal, Cilt: 38 - Sayı: 1, 32–37. https://ajindex.com/articles/223511

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Kovacs K, Horvath E. Tumors of the pituitary gland. In: Harthmann WH, Sobin LH, eds Atlas of Tumor Pathology, fascicle 21 Washing- ton DC: Armed Forces Institute of Pathology. 1986: 1-269.
  2. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003; 148(4): 433-42. [CrossRef] Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996; 17(6): 610-38.
  3. Sanno N, Teramoto A, Osamura RY, Horvath E, Kovacs K, Lloyd RV, et al. Pathology of pituitary tumors. Neurosurg Clin N Am 2003; 14(1): 25-39. [CrossRef] Childress RD, Qureshi MN, Kasparova M, Oktaei H, Williams-Cleaves B, Solomon SS. Thyrotoxicosis presenting as hypogonadism: a case of central hyperthyroidism. Am J Med Sci 2004; 328(5): 295-8. [CrossRef] Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999; 84(2): 476-86. [CrossRef] Beck-Peccoz P, Persani L, Mannavola D, Campi I. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009; 23(5): 597-606. [CrossRef] Lee MT, Wang CY. Concomitant Graves hyperthyroidism with thy- rotrophin-secreting pituitary adenoma. South Med J 2010; 103(4): 347-9. [CrossRef] Ogawa Y, Tominaga T. Thyroid-stimulating hormone-secreting pi- tuitary adenoma presenting with recurrent hyperthyroidism in post- treated Graves' disease: a case report. J Med Case Rep 2013; 7(1): 27. [CrossRef] Kamoi K, Mitsuma T, Sato H, Yokoyama M, Washiyama K, Tanaka R, et al. Hyperthyroidism caused by a pituitary thyrotrophin-secreting tu- mour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves' disease in a middle-aged woman. Acta Endocrinol (Copenh) 1985; 110(3): 373-82. [CrossRef] Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T, et al. Thyrotropin-producing pituitary adenoma associated with Graves' disease. Eur J Endocrinol. 2004; 151(5): 587-94. [CrossRef] Kamoun M, d'Herbomez M, Lemaire C, Fayard A, Desailloud R, Hu- glo D, et al. Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and graves' hyperthyroidism. Eur Thyroid J 2014; 3(1): 60-4.
  4. Refetoff S, Weiss RE, Usala SJ. The syndro